logo-loader

IXICO to provide data analytics and neuroimaging services to a late-stage Huntington's programme

Last updated: 14:05 05 Mar 2019 GMT, First published: 07:48 05 Mar 2019 GMT

brain scan
Huntington's disease is an inherited disorder that results in the death of brain cells

IXICO PLC (LON:IXI) said it will provide data analytics and neuroimaging services to a late-stage programme for people with the degenerative brain disorder Huntington's disease.

Its expertise will be used in what’s called an extension study to allow people living with Huntington's to continue to contribute to the search for a treatment for the condition. IXICO’s involvement will generate a further £500,000 in revenues.

WATCH: IXICO to support late phase clinical research programme in Huntington's disease

“The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development," said chief executive Giulio Cerroni.

In a note to clients, analysts at ‘house’ broker Shore Capital commented: “The extension is further evidence of IXICO’s momentum in Huntington’s disease, having agreed four new contracts for the condition in its last financial year, including a £9.1mln agreement for a pivotal Phase III trial announced in September.”

In afternoon trading, IXICO shares eased back after hitting an early session high of 32p, losing a penny at 29.50p.

 -- Adds analyst comment, share price --

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

49 minutes ago